Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
نویسندگان
چکیده
DAA: direct antiviral agents HCV: hepatitis C virus LP: lichen planus INTRODUCTION Lichen planus (LP) is a chronic inflammatory disease affecting the skin and mucosa of squamous cell origin and has a significantly higher prevalence in patients infected with the hepatitis C virus (HCV). Although ribavirin-based treatments frequently show exacerbations of these lesions, currently there is little information on the response of HCVassociated LP to newer direct antiviral agents (DAA), such as ledipasvir-sofosbuvir (Harvoni; Gilead Sciences, Foster City, CA).
منابع مشابه
Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma
Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP acco...
متن کاملDetection of Pre-treatment mutations leading to resistance to direct hepatitis C virus blocking drugs in patients with chronic hepatitis C
Background and objective: Human is the only host of hepatitis C virus. This virus has a positive single stranded RNA and lipoprotein envelop that has 7 confirmed genotypes. According to studies, genotypes 1a, 3a and 1b are the most common genotypes in Iran. No effective vaccine against HCV infection has been developed instead, advances in antiviral treatment using drugs that directly affect spe...
متن کاملCombination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of care. Recently, a new treatment, which is a combination of two direct-acting antiviral agents, ledipasvir 90 mg (anti-NS5A) and sofosbuvir 400 mg (anti-NS5B), has been approved in the US and the European Union for the treatment of chronic hepa...
متن کاملCaring Ambassadors Program Hepatitis C Literature Review
Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir. Wyles D1, Dvory-Sobol H2, Svarovskaia Doehle ES3, et al. J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699-7. doi: 10.1016/j.jhep.2016.11.022. [Epub ahead of print] BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase 3 clinical trials, resulted in sustained vir...
متن کاملبررسی فراوانی لیکن پلان دهانی در بیماران مبتلا به عفونت با ویروس هپاتیت C و عوامل موثر بر آن
Background: Hepatitis C is a major cause of chronic liver disease and hepatocellular carcinoma. Hepatitis C infection also has extrahepatic manifestations, including cryoglobulinemia and lichen planus. Lichen planus is a relatively common mucocutaneous disorder, and, due to its chronic pattern and increased incidence of malignancy, diagnosis and treatment of this disease are very important. The...
متن کامل